Evaxion Biotech A/S
EVAX
$1.65
$0.063.77%
NASDAQ
| 12/31/2024 | 06/30/2024 | 12/31/2023 | 09/30/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -- | -- | 26.13% | 45.64% | 45.64% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | -11.86% | -7.95% | -7.95% |
| Operating Income | -- | -- | 12.15% | 7.95% | 7.95% |
| Income Before Tax | -- | -- | 4.29% | -5.49% | -5.49% |
| Income Tax Expenses | -- | -- | -2.33% | -208.56% | -208.56% |
| Earnings from Continuing Operations | -- | -- | 4.51% | 0.79% | 0.79% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | 4.51% | 0.79% | 0.79% |
| EBIT | -- | -- | 12.15% | 7.95% | 7.95% |
| EBITDA | -- | -- | 13.52% | 9.38% | 9.38% |
| EPS Basic | -- | -- | 16.31% | 11.97% | 11.97% |
| Normalized Basic EPS | -- | -- | 40.90% | 30.04% | 30.04% |
| EPS Diluted | -- | -- | 16.31% | 11.97% | 11.97% |
| Normalized Diluted EPS | -- | -- | 40.90% | 30.04% | 30.04% |
| Average Basic Shares Outstanding | -- | -- | 14.97% | 12.28% | 12.29% |
| Average Diluted Shares Outstanding | -- | -- | 15.34% | 12.28% | 12.77% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |